Latest Information Update: 25 Mar 2008
At a glance
- Originator Neuromed Pharmaceuticals
- Class Antimigraines
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 25 Mar 2008 Discontinued - Preclinical for Migraine in Canada (unspecified route)
- 08 Mar 2006 Neuromed Technologies is now called Neuromed Pharmaceuticals
- 29 Oct 2001 New profile